Technology transfer / Localization · GCC · Announced 27 Nov 2025
Bayer → Alfa Pharma
Bayer and Alfa Pharma signed an MoU, under the auspices of Saudi Arabia's LCGPA, to localise manufacture of Aspirin Protect at Alfa's KAEC plant, with full local production planned for 2028.
Parties: Bayer (Germany) → Alfa Pharma (Saudi Arabia)
- Deal type
- Technology transfer / Localization
- Value
- Undisclosed
- Territory
- Saudi Arabia (manufacture at Alfa Pharma, King Abdullah Economic City)
- Therapeutic area
- Cardiovascular
- Asset
- Aspirin Protect
- Announced
- 27 Nov 2025
Our analysis
Why this matters
On 27 November 2025, Bayer and Alfa Pharma announced a memorandum of understanding to localise manufacturing of Aspirin Protect in Saudi Arabia, under the auspices of the Local Content and Government Procurement Authority (LCGPA). The agreement covers local manufacturing and the transfer of Bayer's manufacturing know-how and production technology to Alfa Pharma's plant in King Abdullah Economic City. Full local production is scheduled to start in 2028. No financial terms were disclosed.
Aspirin Protect is Bayer's low-dose aspirin brand for cardiovascular prevention, a high-volume product in the Saudi market.
The full analysis is free to read with a work email on this page.
Source: Souq Al Dawaa Saudi